Open AccessPotential effectiveness of combining bevacizumab with paclitaxel for treating HER2-positive metastatic breast cancer
Author(s) -
Mai Hamada-Nishimoto,
Yookija Kang,
Eriko Shiraki,
Shigeru Tsuyuki
Publication year - 2021
Publication title -
international cancer conference journal
Language(s) - English
Resource type - Journals
ISSN - 2192-3183
DOI - 10.1007/s13691-021-00504-z
Subject(s) - bevacizumab , medicine , metastatic breast cancer , paclitaxel , oncology , breast cancer , targeted therapy , trastuzumab , cancer , chemotherapy , her2 negative
Although various first- to third-line HER2-targeted therapies have been established, the optimal sequence after third-line therapy has not been determined yet. Here, we describe seven patients with HER2-positive metastatic breast cancer who underwent bevacizumab (BV) and paclitaxel (PTX) combination therapy after several HER2-targeted therapies. Re-biopsy of metastatic sites was performed on four patients during the treatment prior to BV + PTX; three patients presented the same HER2-positive status as that of the primary tumor and two of whom achieved partial response. Four of seven patients achieved partial response and a 10-month median progression-free survival. Therefore, bevacizumab combined with paclitaxel is potentially effective in the treatment of HER2-positive metastatic breast cancer, if standard HER2-targeted therapy fails.